Back to Search
Start Over
Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms.
- Source :
-
Gastroenterology [Gastroenterology] 2021 Jun; Vol. 160 (7), pp. 2435-2450.e34. Date of Electronic Publication: 2021 Mar 04. - Publication Year :
- 2021
-
Abstract
- Background & Aims: Given that gastrointestinal (GI) symptoms are a prominent extrapulmonary manifestation of COVID-19, we investigated intestinal infection with SARS-CoV-2, its effect on pathogenesis, and clinical significance.<br />Methods: Human intestinal biopsy tissues were obtained from patients with COVID-19 (n = 19) and uninfected control individuals (n = 10) for microscopic examination, cytometry by time of flight analyses, and RNA sequencing. Additionally, disease severity and mortality were examined in patients with and without GI symptoms in 2 large, independent cohorts of hospitalized patients in the United States (N = 634) and Europe (N = 287) using multivariate logistic regressions.<br />Results: COVID-19 case patients and control individuals in the biopsy cohort were comparable for age, sex, rates of hospitalization, and relevant comorbid conditions. SARS-CoV-2 was detected in small intestinal epithelial cells by immunofluorescence staining or electron microscopy in 15 of 17 patients studied. High-dimensional analyses of GI tissues showed low levels of inflammation, including down-regulation of key inflammatory genes including IFNG, CXCL8, CXCL2, and IL1B and reduced frequencies of proinflammatory dendritic cells compared with control individuals. Consistent with these findings, we found a significant reduction in disease severity and mortality in patients presenting with GI symptoms that was independent of sex, age, and comorbid illnesses and despite similar nasopharyngeal SARS-CoV-2 viral loads. Furthermore, there was reduced levels of key inflammatory proteins in circulation in patients with GI symptoms.<br />Conclusions: These data highlight the absence of a proinflammatory response in the GI tract despite detection of SARS-CoV-2. In parallel, reduced mortality in patients with COVID-19 presenting with GI symptoms was observed. A potential role of the GI tract in attenuating SARS-CoV-2-associated inflammation needs to be further examined.<br /> (Copyright © 2021 AGA Institute. All rights reserved.)
- Subjects :
- Aged
Aged, 80 and over
COVID-19 diagnosis
COVID-19 immunology
COVID-19 mortality
Case-Control Studies
Cells, Cultured
Cytokines blood
Female
Gastrointestinal Diseases diagnosis
Gastrointestinal Diseases immunology
Gastrointestinal Diseases mortality
Host-Pathogen Interactions
Humans
Inflammation Mediators blood
Intestinal Mucosa immunology
Italy
Male
Middle Aged
New York City
Prognosis
Risk Assessment
Risk Factors
SARS-CoV-2 immunology
Viral Load
COVID-19 virology
Gastrointestinal Diseases virology
Immunity, Mucosal
Intestinal Mucosa virology
SARS-CoV-2 pathogenicity
Subjects
Details
- Language :
- English
- ISSN :
- 1528-0012
- Volume :
- 160
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Gastroenterology
- Publication Type :
- Academic Journal
- Accession number :
- 33676971
- Full Text :
- https://doi.org/10.1053/j.gastro.2021.02.056